IL-20RA hFc Chimera, Human
IL-20RA HFc Chimera, Human

The purity of IL-20RA hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

IL-20RA HFc Chimera, Human

IL-20RA hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

IL-20RA hFc Chimera, Human

IL-20RA was highly expressed in the tumor tissue of CRC and related to the advanced stage.IL-20RA was involved in regulating oncogenic and immune pathways and affecting the expression of genes related to cell proliferation and immune evasion in CRC.Super-enhancer inhibition by JQ-1 or iBET-151 suppressed the growth of tumor cells and inhibited the expression of IL-20RA.
Z05474
¥55,963.00

Ask us a question
Product Introduction
Species Human
Protein Construction
IL-20RA (Val30-Lys250)
Accession # Q9UHF4-1		 hFc
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Human IL­20RA, hFc Tag captured on CM5 Chip via Protein A can bind Human IL­20, His Tag in SPR assay (Biacore T200). Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 52 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 65-70 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • IL-20RA HFc Chimera, Human
    • IL-20RA HFc Chimera, Human

    The purity of IL-20RA hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

  • IL-20RA HFc Chimera, Human
    • IL-20RA HFc Chimera, Human

    IL-20RA hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background IL-20RA was highly expressed in the tumor tissue of CRC and related to the advanced stage.IL-20RA was involved in regulating oncogenic and immune pathways and affecting the expression of genes related to cell proliferation and immune evasion in CRC.Super-enhancer inhibition by JQ-1 or iBET-151 suppressed the growth of tumor cells and inhibited the expression of IL-20RA.
Synonyms IL-20R-alpha; IL-20RA; CRF2-8; IL-20R1; ZcytoR7; FLJ40993

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.